Ocugen Inc logo

OCGN

Ocugen Inc

$2.56

Earnings Summary

Revenue
$0Mn
Net Profits
$-18.02Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Ocugen Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Ocugen Inc has generated -100% fall in its revenue since last 3-months.

Net Profits:

Ocugen Inc’s net profit fell -154.61% since last year same period to $-18.02Mn in the Q1 2022. On a quarterly growth basis, Ocugen Inc has generated -23.58% fall in its net profits since last 3-months.

Net Profit Margins:

Ocugen Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Ocugen Inc has generated -Inf% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ocugen Inc post its latest quarter earnings

EPS Estimate Current Year
-0.08

Highlights

EPS Estimate Current Year:

Ocugen Inc’s earning per share (EPS) estimates for the current year stand at -0.08.

Key Ratios

Key ratios of the Ocugen Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.09
Return on Assets (ROA)
-0.31
Return on Equity (ROE)
-0.55
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Ocugen Inc’s earning per share (EPS) fell -125% since last year same period to -0.09 in the Q1 2022. This indicates that the Ocugen Inc has generated -125% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ocugen Inc’s return on assets (ROA) stands at -0.31.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ocugen Inc’s return on equity (ROE) stands at -0.55.

Dividend Per Share (DPS):

Ocugen Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-02-28
-0.06
-0.07
-16.67%
2021-05-07
0.5
-0.04
-108%
2021-11-09
-0.04
-0.05
-25%
2021-08-06
-0.03
-0.13
-333.33%

Company Information

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug - "one to many" and its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The Company is co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.

Organisation
Ocugen Inc
Headquarters
Malvern, Pennsylvania, US
Employees
15
Industry
Health Technology
CEO
Shankar Musunuri